Dapiprazole
Not to be confused with Aripiprazole.
Systematic (IUPAC) name | |
---|---|
3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8- tetrahydro-[1,2,4]triazolo[4,5-a]pyridine | |
Clinical data | |
AHFS/Drugs.com | Consumer Drug Information |
MedlinePlus | a601043 |
Pregnancy category |
|
Routes of administration | Topical (eye drops) |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Negligible when administered topically |
Identifiers | |
CAS Number | 72822-12-9 |
ATC code | S01EX02 (WHO) |
PubChem | CID 3033538 |
IUPHAR/BPS | 7155 |
DrugBank | DB00298 |
ChemSpider | 2298190 |
UNII | 5RNZ8GJO7K |
KEGG | D07775 |
ChEBI | CHEBI:51066 |
ChEMBL | CHEMBL1201216 |
Chemical data | |
Formula | C19H27N5 |
Molar mass | 325.451 g/mol |
| |
| |
(what is this?) (verify) |
Dapiprazole (Rev-Eyes) is an alpha blocker. It is used to reverse mydriasis after eye examination.[1]
References
- ↑ Doughty, Michael J.; Lyle, William M. (May 1992). "A Review of the Clinical Pharmacokinetics of Pilocarpine, Moxisylyte (Thymoxamine), and Dapiprazole in the Reversal of Diagnostic Pupillary Dilation". Optometry & Vision Science 69 (5).
|
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.